Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 51655-973

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 51655-973). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 973 87 Master Bottle Label Approval Rev A 05 22)

Label (51655 973 87 Master Bottle Label Approval   Rev A 05 22)
NDC 51655-973-87 Cyclobenzaprine Hydrochloride Tablets USP 10mg, 6 tablets. It's a prescription medicine and the dosage should be taken as per the package insert. The tablets should be stored at a controlled room temperature and kept away from the reach of children. This particular product has been repackaged by Northwind Pharmaceuticals. The GTIN is 0351655973875 and the serial number is 000000000000000. The product expiration date is 00/00/0000 and LOT number is 0000000000.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
This is a list of side effects and their corresponding percentages of cyclobenzaprine HCI tablets at two dosage strengths and a placebo. The side effects include drowsiness, dry mouth, fatigue, headache, and are presented in percentage of occurrence.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
Cyclobenzaprine HCl Tablets, 10 mg have undergone clinical studies which have found that they can cause drowsiness in 39% of individuals using them, dry mouth in 2%, and dizziness in 1%. Additionally, a surveillance program has found that 16% of individuals using these tablets may experience drowsiness, 7% may experience dry mouth, and 3% may experience dizziness.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.